Board revokes patent on Roche hepatitis drug

MUMBAI Fri Nov 2, 2012 7:23pm IST

A pharmacist gives medicine to a patient inside a government hospital in Kolkata July 3, 2012. REUTERS/Rupak De Chowdhuri/Files

A pharmacist gives medicine to a patient inside a government hospital in Kolkata July 3, 2012.

Credit: Reuters/Rupak De Chowdhuri/Files

Related Topics

Stocks

   

MUMBAI (Reuters) - India's patents appeal board has revoked a patent granted to Roche's hepatitis C drug Pegasys, citing a lack of evidence the drug is superior tp existing treatments, and its high price.

The decision is another setback for large pharmaceutical companies in India, which earlier this year granted the first ever compulsory licence to domestic drugmaker Natco (NATP.NS) to sell cheap copies of Bayer AG's(BAYGn.DE) cancer drug Nexavar.

Global drugmakers see India's $12 billion drug market as a huge opportunity, but they are wary of protection for intellectual property in a country where generic medicines account for more than 90 percent of sales.

Sankalp Rehabilitation Trust, an advocacy group for cheaper medicines, challenged the Pegasys patent with the Intellectual Property Appellate Board, saying the drug was costly and gave the Swiss company a monopoly in the market for the drug.

The market price of Pegasys is 436,000 rupees for 48 weeks of treatment, and it is also available at a discounted price of 314,496 rupees, Sankalp said in a statement.

Pegasys is to be taken in combination with another drug, ribavirin, which costs 47,160 rupees for the same period, Sankalp added.

The appeals board on Friday termed Sankalp's plea "valid."

Roche, which can appeal the decision to India's Supreme Court, could not immediately be reached for comment.

(Reporting by Kaustubh Kulkarni; Editing by Tony Munroe and Helen Massy-Beresford)

FILED UNDER:

Reuters Showcase

Uber's Woes

Uber's Woes

Uber, other taxi-hailing apps hit new roadblock in Delhi.  Full Article 

Transfer Pricing

Transfer Pricing

India's Vodafone decision eases tax worries for Shell, others.  Full Article 

Facebook Earnings

Facebook Earnings

Facebook tops Wall Street revenue target in 4th quarter.  Full Article 

Governance Reforms

Governance Reforms

IMF sets June deadline for progress on governance reforms.  Full Article 

Fed's Stance

Fed's Stance

Fed upbeat on U.S. economy, cites strong job gains.  Full Article 

Tumultuous Run

Tumultuous Run

McDonald's CEO Don Thompson leaving.  Full Article 

Samsung Results

Samsung Results

Samsung Elec's smartphone primacy under threat from Apple after weak Q4.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage